中东和非洲轻度认知障碍（Mci）治疗市场

市场分析和洞察：中东和非洲轻度认知障碍 (MCI) 治疗市场

轻度认知障碍 (MCI) 治疗市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，该市场的复合年增长率为 6.4%，预计到 2029 年将达到 3,981.49 万美元。主要参与者提供的广泛产品组合和对轻度认知障碍的日益认识预计将成为市场增长的驱动力。

轻度认知障碍 (MCI) 是记忆丧失或其他认知能力丧失（如语言或视觉/空间感知）的早期阶段，适用于能够独立完成大部分日常生活活动的个人。MCI 可能由多种原因引起，患有 MCI 的个人可能会患上痴呆症。MCI 可能是神经退行性疾病（包括阿尔茨海默氏症）疾病连续体的早期阶段。在某些人中，MCI 会恢复正常认知或保持稳定。

轻度认知障碍 (MCI) 的特征是单一认知领域受损，通常是记忆（遗忘性 MCI），或多个认知领域中度受损。长期护理环境中的 MCI 患病率从许多养老院的 5% 到 10% 不等，最高可达 30%。最常见的 MCI 形式是遗忘型。不太常见的 MCI 变体表现为其他认知领域的局部损伤，例如额颞叶变性 (FTLD) 中的执行功能障碍。

推动全球轻度认知障碍 (MCI) 治疗市场增长的主要因素是老年患者人数的增加，持续的研究以寻找完美有效的治疗方法预计将在未来推动市场的增长。然而，治疗程序的高成本和与产品相关的不良风险可能会阻碍市场的增长。

The mild cognitive impairment (MCI) treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the Mild Cognitive Impairment (MCI) Treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Mild Cognitive Impairment (MCI) Treatment Market Scope and Market Size

The mild cognitive impairment (MCI) treatment market is segmented on basis of disease type, treatment type, route of administration, drug type, gender, age, distribution channel, and end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on disease type, the mild cognitive impairment (MCI) treatment market is segmented into amnestic MCI and non-amnestic MCI. In 2022, the amnestic MCI segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to the increase in the older population across the globe.
Based on treatment type, the mild cognitive impairment (MCI) treatment market is segmented into medication and therapy. In 2022, the medication segment is expected to dominate the global mild cognitive impairment (MCI) treatment market due to its immediate and effective impact on MCI symptoms.
Based on route of administration, the mild cognitive impairment (MCI) treatment market is segmented into oral and parenteral, and others. In 2022, the oral segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to the non-invasive, high patient compliance, convenience handling, and not requiring any specific sterile conditions.
Based on drug type, the mild cognitive impairment (MCI) treatment market is segmented into branded and generics. In 2022, the generics segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to the cost-effectiveness compared to branded drugs.
Based on gender, the mild cognitive impairment (MCI) treatment market is segmented into male and female. In 2022, the male segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to a surge in mental health complications observed in the male population.
Based on age, the mild cognitive impairment (MCI) treatment market is segmented into child, adult, and geriatric. In 2022, the geriatric segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to a surge in vulnerable older people population with the highest rate of increase in the Asian region.
Based on end users, the mild cognitive impairment (MCI) treatment market is segmented into hospitals, specialty clinics, homecare, and others. In 2022, the hospital segment is expected to dominate the global mild cognitive impairment (MCI) treatment market due to increased awareness regarding better and more effective treatment during hospital stays.
Based on distribution channel, the mild cognitive impairment (MCI) treatment market is segmented into hospital pharmacies, retail pharmacy. In 2022, the hospital pharmacy segment is expected to dominate the global mild cognitive impairment (MCI) treatment market due to increased interaction with certified prescribers and health professionals to use antipsychotic drugs and guaranteed payment.

Mild Cognitive Impairment (MCI) Treatment Market Country Level Analysis

The mild cognitive impairment (MCI) treatment market is analyzed and market size information is provided by the country, disease type, treatment type, route of administration, drug type, gender type, age, distribution channel, and end users as referenced above.

The countries covered in the mild cognitive impairment (MCI) treatment market report are the South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Kuwait and rest of Middle East and Africa.

South Africa is expected to dominate the mild cognitive impairment (MCI) treatment market due to the increasing geriatric population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing strategic activities by major market players to enhance the awareness for mild cognitive impairment (MCI) treatment, is boosting the market growth of mild cognitive impairment (MCI) treatment market.

The mild cognitive impairment (MCI) treatment market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.

Competitive Landscape and Mild Cognitive Impairment (MCI) Treatment Market Share Analysis

轻度认知障碍 (MCI) 治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对轻度认知障碍 (MCI) 治疗市场的关注有关。

轻度认知障碍 (MCI) 治疗市场的一些主要参与者包括辉瑞公司、霍夫曼罗氏有限公司、诺华公司、Accord UK 有限公司、雷迪博士实验室有限公司、Hikma Pharmaceuticals PLC、Viatris 公司、卫材株式会社、太阳制药有限公司、强生服务公司、梯瓦制药工业有限公司、Mallinckrodt、阿斯利康、西普拉公司、武田制药有限公司、Allergan Aesthetics、Lupin、Jubilant Pharmova 有限公司、Lannett、Aurobindo Pharma、UCB SA、Belgian 和 WOCKHARDT 等。

例如，

2021 年 7 月，FDA 通过加速审批途径批准 Biogen Aduhelm (aducanumab) 用于治疗阿尔茨海默病患者

市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业和其他策略正在增强公司在轻度认知障碍 (MCI) 治疗市场的影响力，这也为组织的利润增长带来了好处。

SKU-67700

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 COMMON BENZODIAZEPINES AVAILABLE IN THE U.S.-

TABLE 2 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 3 MIDDLE EAST & AFRICA AMNESTIC MCI IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 4 MIDDLE EAST & AFRICA NON-AMNESTIC MCI IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 5 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 6 MIDDLE EAST & AFRICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 7 MIDDLE EAST & AFRICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 8 MIDDLE EAST & AFRICA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 9 MIDDLE EAST & AFRICA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 10 MIDDLE EAST & AFRICA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 11 MIDDLE EAST & AFRICA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 12 MIDDLE EAST & AFRICA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 13 MIDDLE EAST & AFRICA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 14 MIDDLE EAST & AFRICA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 15 MIDDLE EAST & AFRICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 16 MIDDLE EAST & AFRICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 17 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 18 MIDDLE EAST & AFRICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 19 MIDDLE EAST & AFRICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 20 MIDDLE EAST & AFRICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 21 MIDDLE EAST & AFRICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 22 MIDDLE EAST & AFRICA OTHERS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 23 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 24 MIDDLE EAST & AFRICA GENERICS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 25 MIDDLE EAST & AFRICA BRANDED IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 26 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 27 MIDDLE EAST & AFRICA MALE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 28 MIDDLE EAST & AFRICA FEMALE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 29 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 30 MIDDLE EAST & AFRICA GERIATRIC IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 31 MIDDLE EAST & AFRICA ADULT IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 32 MIDDLE EAST & AFRICA CHILD IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 33 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 34 MIDDLE EAST & AFRICA HOSPITALS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 35 MIDDLE EAST & AFRICA SPECIALITY CLINICS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 36 MIDDLE EAST & AFRICA HOMECARE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 37 MIDDLE EAST & AFRICA OTHERS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 38 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 39 MIDDLE EAST & AFRICA HOSPITAL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40 MIDDLE EAST & AFRICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 41 MIDDLE EAST & AFRICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 42 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 43 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 44 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 45 MIDDLE EAST AND AFRICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 46 MIDDLE EAST AND AFRICA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 47 MIDDLE EAST AND AFRICA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 48 MIDDLE EAST AND AFRICA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 49 MIDDLE EAST AND AFRICA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 50 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 51 MIDDLE EAST AND AFRICA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 52 MIDDLE EAST AND AFRICA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 53 MIDDLE EAST AND AFRICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 54 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 55 MIDDLE EAST AND AFRICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 56 MIDDLE EAST AND AFRICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 57 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 58 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 59 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 60 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 61 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 62 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 63 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 64 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 65 SOUTH AFRICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 66 SOUTH AFRICA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 67 SOUTH AFRICA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 68 SOUTH AFRICA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 69 SOUTH AFRICA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 70 SOUTH AFRICA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 71 SOUTH AFRICA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 72 SOUTH AFRICA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 73 SOUTH AFRICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 74 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 75 SOUTH AFRICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 76 SOUTH AFRICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 77 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 78 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 79 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 80 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 81 SOUTH AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 82 SOUTH AFRICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 83 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 84 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 85 EGYPT MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 86 EGYPT CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 87 EGYPT BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 88 EGYPT GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 89 EGYPT MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 90 EGYPT PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 91 EGYPT ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 92 EGYPT ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 93 EGYPT THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 94 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 95 EGYPT ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 96 EGYPT PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 97 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 98 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 99 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 100 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 101 EGYPT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 102 EGYPT RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 103 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 104 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 105 SAUDI ARABIA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 106 SAUDI ARABIA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 107 SAUDI ARABIA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 108 SAUDI ARABIA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 109 SAUDI ARABIA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 110 SAUDI ARABIA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 111 SAUDI ARABIA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 112 SAUDI ARABIA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 113 SAUDI ARABIA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 114 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 115 SAUDI ARABIA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 116 SAUDI ARABIA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 117 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 118 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 119 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 120 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 121 SAUDI ARABIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 122 SAUDI ARABIA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 123 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 124 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 125 UAE MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 126 UAE CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 127 UAE BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 128 UAE GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 129 UAE MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 130 UAE PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 131 UAE ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 132 UAE ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 133 UAE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 134 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 135 UAE ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 136 UAE PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 137 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 138 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 139 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 140 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 141 UAE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 142 UAE RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 143 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 144 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 145 ISRAEL MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 146 ISRAEL CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 147 ISRAEL BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 148 ISRAEL GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 149 ISRAEL MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 150 ISRAEL PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 151 ISRAEL ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 152 ISRAEL ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 153 ISRAEL THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 154 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 155 ISRAEL ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 156 ISRAEL PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 157 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 158 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 159 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 160 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 161 ISRAEL MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 162 ISRAEL RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 163 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 164 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 165 KUWAIT MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 166 KUWAIT CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 167 KUWAIT BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 168 KUWAIT GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 169 KUWAIT MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 170 KUWAIT PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 171 KUWAIT ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 172 KUWAIT ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 173 KUWAIT THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 174 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 175 KUWAIT ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 176 KUWAIT PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 177 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 178 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 179 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 180 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 181 KUWAIT MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 182 KUWAIT RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 183 REST OF MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

图片列表

FIGURE 1 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: END USERS COVERAGE GRID

FIGURE 8 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE AND ASIA-PACIFIC IS ESTIMATED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 ONGOING RESEARCH TO INCREASE THE THERAPEUTICS APPLICATION IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 AMNESTIC MCI SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET IN 2022 & 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET

FIGURE 15 DISEASE BURDEN BY RISK FACTOR, WORLDWIDE, 2019

FIGURE 16 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, 2021

FIGURE 17 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

FIGURE 18 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, CAGR (2022-2029)

FIGURE 19 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 20 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, 2021

FIGURE 21 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, 2020-2029 (USD THOUSAND)

FIGURE 22 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, CAGR (2022-2029)

FIGURE 23 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 24 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 25 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

FIGURE 26 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 27 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 28 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, 2021

FIGURE 29 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, 2020-2029 (USD THOUSAND)

FIGURE 30 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, CAGR (2022-2029)

FIGURE 31 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 32 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, 2021

FIGURE 33 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, 2020-2029 (USD THOUSAND)

FIGURE 34 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, CAGR (2022-2029)

FIGURE 35 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 36 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, 2021

FIGURE 37 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, 2020-2029 (USD THOUSAND)

FIGURE 38 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, CAGR (2022-2029)

FIGURE 39 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, LIFELINE CURVE

FIGURE 40 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, 2021

FIGURE 41 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, 2020-2029 (USD THOUSAND)

FIGURE 42 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, CAGR (2022-2029)

FIGURE 43 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 44 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 45 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

FIGURE 46 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 47 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 48 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 49 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2021)

FIGURE 50 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 51 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 52 MIDDLE EAST AND AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE (2022-2029)

FIGURE 53 MIDDLE EAST & AFRICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY SHARE 2021 (%)

查看详细信息

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

At what growth rate will the market be projected to grow during the forecast period of 2022 to 2029?

Middle East and Africa Mild Cognitive Impairment (MCI) Treatment Market is growing with a CAGR of 6.4% during the forecast period of 2022 to 2029.

What will be the market value in the future?

Middle East and Africa Mild Cognitive Impairment (MCI) Treatment Market value of USD 3,981.49 thousand during the forecast period of 2022 to 2029.

What are the key opportunities of the market?

The mild cognitive impairment (MCI) treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market.

Who are the major players operating in the market?

The major players operating in the mild cognitive impairment (MCI) treatment market are Pfizer Inc., F. Hoffman La Roche Ltd, Novartis AG, Accord UK Ltd, Dr. Reddy’s laboratories Ltd, Hikma Pharmaceuticals PLC, Viatris Inc., Eisai. Co. Ltd., Sun Pharmaceuticals ltd., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt, AstraZeneca, Cipla Inc., Takeda Pharmaceutical Company Limited, Allergan Aesthetics, Lupin, Jubilant Pharmova Limited, Lannett, Aurobindo Pharma, UCB S.A., Belgium, and WOCKHARDT, among others.